본문 바로가기
KERD
논문KCI 등재

소아에서 시행한 초급속 면역 치료의 안전성

Safety of ultrarush allergen subcutaneous immunotherapy in children with allergic disease

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

주제분류소아과학

초록

Purpose: Ultrarush immunotherapy (ultra-RIT) is more convenient and higher compliant than conventional immunotherapy, but it has rarely used in clinical practice due to severe systemic reactions. This study aimed to determine the safety of ultra-RIT in children and adolescents. Methods: We investigated 19 patients who received ultra-RIT with the same schedule between January 2011 and May 2016. They were sensitized to house dust mites (HDMs) and/or pollen and had their symptoms associated with positive allergens. Over a 1-day hospitalization period, all patients received ultra-RIT subcutaneously 3 times, increasing at hourly intervals. Systemic reactions were classified according to the World Allergy Organization grade system. Results: Systemic reactions occurred in 14 patients (73.7%). The mean time to adverse reactions after the last injection was 36 minutes, and the majority of systemic reactions were pruritus and urticaria. In addition, the injection of HDM alone or HDM plus pollen caused more than grade 2 systemic reactions in about 50% each of the patients. Conclusion: Since ultra-RIT caused a higher incidence of systemic reactions in children and adolescents, it should be carried out cautiously in the hospitalization rather than the office.

Abstract

Purpose: Ultrarush immunotherapy (ultra-RIT) is more convenient and higher compliant than conventional immunotherapy, but it has rarely used in clinical practice due to severe systemic reactions. This study aimed to determine the safety of ultra-RIT in children and adolescents. Methods: We investigated 19 patients who received ultra-RIT with the same schedule between January 2011 and May 2016. They were sensitized to house dust mites (HDMs) and/or pollen and had their symptoms associated with positive allergens. Over a 1-day hospitalization period, all patients received ultra-RIT subcutaneously 3 times, increasing at hourly intervals. Systemic reactions were classified according to the World Allergy Organization grade system. Results: Systemic reactions occurred in 14 patients (73.7%). The mean time to adverse reactions after the last injection was 36 minutes, and the majority of systemic reactions were pruritus and urticaria. In addition, the injection of HDM alone or HDM plus pollen caused more than grade 2 systemic reactions in about 50% each of the patients. Conclusion: Since ultra-RIT caused a higher incidence of systemic reactions in children and adolescents, it should be carried out cautiously in the hospitalization rather than the office.

참고문헌 (36)

  1. Jutel M, "International consensus on allergy immunotherapy", J Allergy Clin Immunol, 136, pp.556~568 (2015)
  2. Roche AM, "Subcutaneous immunotherapy", Int Forum Allergy Rhinol, 4(Suppl 2), pp.S51~S54 (2014)
  3. Cox L, "Accelerated immunotherapy schedules: review of efficacy and safety", Ann Allergy Asthma Immunol, 97, pp.126~137 (2006)
  4. Des Roches A, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children", J Allergy Clin Immunol, 99, pp.450~453 (1997)
  5. Purello-D'Ambrosio F, "Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study", Clin Exp Allergy, 31, pp.1295~1302 (2001)
  6. Rhodes BJ, "Patient dropouts before completion of optimal dose, multiple allergen immunotherapy", Ann Allergy Asthma Immunol, 82, pp.281~286 (1999)
  7. 현세은, "집먼지 진드기 항원을 이용한 초급속면역치료의 안전성과 효과", Korean Journal of Pediatrics, 51(8), pp.868~873 (2008), 대한소아과학회
  8. 김명은, "Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis", Journal of Korean Medical Science, 26(9), pp.1159~1164 (2011), 대한의학회
  9. Castro-Rodríguez JA, "A clinical index to define risk of asthma in young children with recurrent wheezing", Am J Respir Crit Care Med, 162(4 Pt 1), pp.1403~1406 (2000)
  10. Crapo RO, "Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999", Am J Respir Crit Care Med, 161, pp.309~329 (2000)
  11. "Korean Guideline for Asthma" (2015)[URL]
  12. Brozek JL, "Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision", J Allergy Clin Immunol, 126, pp.466~476 (2010)
  13. Esch RE, "Allergen immunotherapy: what can and cannot be mixed?", J Allergy Clin Immunol, 122, pp.659~660 (2008)
  14. Calderón MA, "Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence", J Allergy Clin Immunol, 129, pp.929~934 (2012)
  15. Lee KU, "A study on the method of exclusion on unnecessary allergens from the vaccines for immunotherapy", J Asthma Allergy Clin Immunol, 8, pp.150~164 (1988)
  16. Lee KY, "Diagnosis and management of allergic disease" (2001), Hangukeuihaksa
  17. Calabria CW, "Accelerated immunotherapy schedules", Curr Allergy Asthma Rep, 13, pp.389~398 (2013)
  18. Cox L, "Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system", J Allergy Clin Immunol, 125, pp.569~574 (2010)
  19. Schaefer P, "Urticaria: evaluation and treatment", Am Fam Physician, 83, pp.1078~1084 (2011)
  20. Kemp SF, "Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization", Allergy, 63, pp.1061~1070 (2008)
  21. 남동호, "알레르기질환에서 면역요법의 현재와 미래", 대한의사협회지, 58(5), pp.433~440 (2015), 대한의사협회[DOI]
  22. Incorvaia C, "Patient's compliance with allergen immunotherapy", Patient Prefer Adherence, 2, pp.247~251 (2008)
  23. Nam YH, "Physician's recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy", Patient Prefer Adherence, 11, pp.381~387 (2017)
  24. Goldberg A, "Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy", Ann Allergy Asthma Immunol, 91, pp.405~410 (2003)
  25. Hejjaoui A, "Systemic reactions occurring during immunotherapy with standardized pollen extracts", J Allergy Clin Immunol, 89, pp.825~933 (1992)
  26. Cox L, "Allergen immunotherapy: a practice parameter third update", J Allergy Clin Immunol, 127(1 Suppl), pp.S1~S55 (2011)
  27. Brehler R, "Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts", Allergy Asthma Proc, 31, pp.e31~e38 (2010)
  28. Morais-Almeida M, "Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age", Asia Pac Allergy, 6, pp.35~42 (2016)
  29. Cardona R, "Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study", Allergol Immunopathol (Madr), 42, pp.90~95 (2014)
  30. Portnoy J, "Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts", Ann Allergy, 73, pp.409~418 (1994)
  31. Akmanlar N, "Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy", Allergol Immunopathol (Madr), 28, pp.213~218 (2000)
  32. Kartal O, "Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey", Immunopharmacol Immunotoxicol, 37, pp.280~286 (2015)
  33. Gastaminza G, "Systemic reactions to immunotherapy: influence of composition and manufacturer", Clin Exp Allergy, 33, pp.470~474 (2003)
  34. Winther L, "Side-effects of allergen-specific immunotherapy: a prospective multi-centre study", Clin Exp Allergy, 36, pp.254~260 (2006)
  35. Borchers AT, "Fatalities following allergen immunotherapy", Clin Rev Allergy Immunol, 27, pp.147~158 (2004)
  36. Pfaar O, "Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD)", Allergo J Int, 23, pp.282~319 (2014)

관련 논문AI추천

집먼지진드기에 감작된 소아 천식 및 알레르기비염에서 피하 및 설하 면역요법 효과 비교이은, 김민주, 양송이, 유진호, 홍수종대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2015 · 제3권 제3호집먼지진드기에 대한 설하면역치료 초기 단계에서 발생한 아나필락시스 1례박청수, 박화영, 안영민, 윤지현, 최수영대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2011 · 제21권 제3호초급속 면역요법의 안전성임대현대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2017 · 제5권 제6호대한천식알레르기학회 알레르기 면역요법 진료지침강성윤, 고영일, 김경훈, 김선태, 김주희, 남동호, 류광희, 민진영, 박경희, 박소영, 박중원, 성명순, 신유섭, 심정연, 안영민, 양은애, 이상민, 이영수, 이용원, 이화영, 정은희, 지혜미, 최선희, 최정희, 하은교, 한두희, 한만용, 대한천식알레르기학회 면역요법/알레르겐연구팀대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2024 · 제12권 제3호소아 다중 식품 아나필락시스 환자에서 밀 경구면역치료 3예염상화, 이수영, 이정민, 이창훈, 이하연, 한혜서대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2022 · 제10권 제4호단일기관 소아 알레르기질환 환자에서 최근 흡입항원 감작 패턴의 변화: 단일기관 연구김정민, 김효빈, 이수진대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2019 · 제7권 제4호

이 간행물의 다른 논문 (10건)